Didier Meulendijks1, J G Coen van Hasselt2, Alwin D R Huitema3, Harm van Tinteren4, Maarten J Deenen1, Jos H Beijnen5, Annemieke Cats6, Jan H M Schellens7. 1. Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 2. Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. 3. Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 5. Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands. 6. Division of Gastroenterology and Hepatology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 7. Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands. Electronic address: j.schellens@nki.nl.
Abstract
BACKGROUND: The objective of this analysis was to determine the factors associated with early onset treatment-related toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. PATIENTS AND METHODS: A total of 1463 patients previously included in a prospective cohort study and treated with standard-of-care capecitabine-based anticancer regimens (monotherapy or combined with other chemotherapy or radiotherapy) were analysed. Logistic regression models were developed to investigate associations between patient- and treatment-related factors and occurrence of early--i.e. cycle one or two--severe (grade ≥ 3) treatment-related toxicity, toxicity-related hospitalisation, and toxicity-related treatment discontinuation. Performance of models was evaluated using receiver-operating characteristic (ROC) curves and internal validity was explored using bootstrap analysis. RESULTS: Among 1463 patients included, 231 patients (16%) experienced early severe toxicity, 132 patients (9%) were hospitalised for toxicity, and 146 patients (10%) discontinued treatment for toxicity; in total, 321 patients (22%) experienced any early toxicity-related adverse outcome. Predictors of early grade ≥ 3 toxicity, after adjustment for treatment regimen, were renal function (odds ratio [OR] 0.85 per 10 ml/min/1.73 m(2), p = 0.0007), body surface area (BSA) (OR 0.33 per m(2), p = 0.0053), age (OR 1.14 per decade, p = 0.0891), and elevated pre-treatment uracil concentrations (OR 2.41 per 10 ng/ml, p = 0.0046). Age was significantly associated with fatal treatment-related toxicity (OR 5.75, p = 0.0008). Area under the ROC curve (AUC) of a model to predict early grade ≥ 3 toxicity was 0.704 (95% confidence interval 0.666-0.743, optimism-corrected AUC 0.690). CONCLUSION: Renal function, BSA, and age, in addition to pre-treatment uracil, are associated with clinically relevant differences in risk of early severe toxicity in patients treated with capecitabine in routine clinical care.
BACKGROUND: The objective of this analysis was to determine the factors associated with early onset treatment-related toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. PATIENTS AND METHODS: A total of 1463 patients previously included in a prospective cohort study and treated with standard-of-care capecitabine-based anticancer regimens (monotherapy or combined with other chemotherapy or radiotherapy) were analysed. Logistic regression models were developed to investigate associations between patient- and treatment-related factors and occurrence of early--i.e. cycle one or two--severe (grade ≥ 3) treatment-related toxicity, toxicity-related hospitalisation, and toxicity-related treatment discontinuation. Performance of models was evaluated using receiver-operating characteristic (ROC) curves and internal validity was explored using bootstrap analysis. RESULTS: Among 1463 patients included, 231 patients (16%) experienced early severe toxicity, 132 patients (9%) were hospitalised for toxicity, and 146 patients (10%) discontinued treatment for toxicity; in total, 321 patients (22%) experienced any early toxicity-related adverse outcome. Predictors of early grade ≥ 3 toxicity, after adjustment for treatment regimen, were renal function (odds ratio [OR] 0.85 per 10 ml/min/1.73 m(2), p = 0.0007), body surface area (BSA) (OR 0.33 per m(2), p = 0.0053), age (OR 1.14 per decade, p = 0.0891), and elevated pre-treatment uracil concentrations (OR 2.41 per 10 ng/ml, p = 0.0046). Age was significantly associated with fatal treatment-related toxicity (OR 5.75, p = 0.0008). Area under the ROC curve (AUC) of a model to predict early grade ≥ 3 toxicity was 0.704 (95% confidence interval 0.666-0.743, optimism-corrected AUC 0.690). CONCLUSION: Renal function, BSA, and age, in addition to pre-treatment uracil, are associated with clinically relevant differences in risk of early severe toxicity in patients treated with capecitabine in routine clinical care.
Authors: Nuala A Helsby; John Duley; Kathryn E Burns; Claire Bonnet; Soo Hee Jeong; Elliott Brenman; Paula Barlow; Katrina Sharples; David Porter; Michael Findlay Journal: Br J Clin Pharmacol Date: 2019-12-12 Impact factor: 4.335
Authors: Kathryn E Burns; Ottiniel Chavani; Soo Hee Jeong; John A Duley; David Porter; Michael Findlay; R Matthew Strother; Nuala A Helsby Journal: Cancer Chemother Pharmacol Date: 2021-03-09 Impact factor: 3.333
Authors: Femke M de Man; G D Marijn Veerman; Esther Oomen-de Hoop; Maarten J Deenen; Didier Meulendijks; Caroline M P W Mandigers; Marcel Soesan; Jan H M Schellens; Esther van Meerten; Teun van Gelder; Ron H J Mathijssen Journal: Ther Adv Med Oncol Date: 2019-04-15 Impact factor: 8.168
Authors: Wen Wee Ma; Muhammad Wasif Saif; Bassel F El-Rayes; Marwan G Fakih; Thomas H Cartwright; James A Posey; Thomas R King; Reid W von Borstel; Michael K Bamat Journal: Cancer Date: 2016-09-13 Impact factor: 6.860
Authors: Jonathan E Knikman; Hans Gelderblom; Jos H Beijnen; Annemieke Cats; Henk-Jan Guchelaar; Linda M Henricks Journal: Clin Pharmacol Ther Date: 2020-11-12 Impact factor: 6.875